Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, arising from hepatocytes — the main functional cells of the liver. Approximately 90% of HCC cases develop in the setting of underlying liver disease, particularly cirrhosis. However, hepatitis B virus (HBV) is uniquely able to cause HCC without cirrhosis by directly integrating into the genome and disrupting tumor-suppressor pathways, making surveillance of all HBV carriers essential regardless of cirrhosis status.

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Surveillance
  6. Diagnosis and Staging
  7. Treatment
  8. Prognosis
  9. Prevention
  10. Recent Research
  11. Key Research Papers
  12. Connections
  13. Featured Videos

1. Overview

Hepatocellular carcinoma is the predominant form of primary liver cancer, accounting for approximately 75–85% of all primary liver malignancies. The remaining primary liver cancers include intrahepatic cholangiocarcinoma and rare tumors such as hepatoblastoma and angiosarcoma.

HCC carries a poor prognosis because it is frequently diagnosed at an advanced stage and because it arises in the setting of underlying liver disease that limits treatment options. Early-stage HCC detected through surveillance programs offers a genuine chance of cure with resection, ablation, or transplantation — making surveillance the single most impactful intervention in high-risk patients.

Key distinguishing features of HCC include:

Back to Table of Contents

2. Epidemiology

HCC is the fifth most common cancer worldwide and the second leading cause of cancer-related death globally, responsible for approximately 830,000 deaths annually. Its geographic distribution is striking and reflects the underlying etiology in each region.

Global burden: Sub-Saharan Africa and East Asia bear the greatest burden of HCC, driven predominantly by endemic chronic HBV infection and co-exposure to aflatoxin B1, a mycotoxin produced by Aspergillus species that contaminates improperly stored grain and groundnuts. In these regions, HCC commonly affects younger adults, often without overt cirrhosis.

Western countries: In North America, Europe, and Australia, HCV historically drove the majority of HCC cases. DAA (direct-acting antiviral) therapy has dramatically reduced new HCV-related cirrhosis, but HCC incidence in the West continues to rise — driven now by the NAFLD/NASH epidemic and alcohol-related liver disease. This shift is accompanied by a change in the typical patient profile: older, more metabolically complex, and often presenting without a classic viral hepatitis history.

Incidence figures:

Incidence trends: HCC incidence in the US tripled between 1975 and 2015, though it has plateaued in recent years as HCV cures reduce one major driver. NAFLD-related HCC is projected to become the leading etiology by 2030.

Back to Table of Contents

3. Pathophysiology

HCC typically develops through a well-characterized multistep progression rooted in chronic liver injury, inflammation, and regeneration. Understanding this progression explains why cirrhosis is such a potent substrate for HCC and why surveillance imaging targets specific nodular lesions.

Cirrhosis-to-HCC sequence:

  1. Chronic hepatocyte injury from virus, alcohol, fat, or toxin triggers repeated cycles of cell death and regeneration.
  2. Regenerative nodules form as surviving hepatocytes proliferate to replace lost cells. These are benign by definition.
  3. Low-grade dysplastic nodules (LGDN) accumulate early somatic mutations. Imaging characteristics remain close to normal liver.
  4. High-grade dysplastic nodules (HGDN) show more pronounced cytologic atypia and may display early arterial neovascularization — a hallmark of malignant transformation.
  5. Early HCC is characterized by vaguely nodular architecture, portal tract invasion, and frank arterial hyperenhancement on contrast imaging.
  6. Progressed/advanced HCC shows frank vascular invasion, satellite nodules, and intrahepatic or distant metastases.

Key molecular drivers:

Angiogenesis: Neovascularization is a defining feature of HCC. As nodules progress from dysplastic to malignant, they develop unpaired arterioles and lose portal blood supply — producing the classic imaging finding of arterial phase hyperenhancement followed by venous-phase washout relative to surrounding liver.

Back to Table of Contents

4. Etiology and Risk Factors

HCC almost always develops against a background of chronic liver disease. Identifying the underlying cause is critical for surveillance strategy, treatment planning, and prevention counseling.

Hepatitis B virus (HBV): The most common cause of HCC worldwide, accounting for approximately 50–55% of global cases. Chronic HBV infection creates HCC risk through both cirrhosis-dependent and cirrhosis-independent mechanisms. Risk is highest with high HBV viral load, HBeAg positivity, genotype C infection, co-infection with hepatitis D virus, male sex, age over 40, and family history of HCC. Antiviral therapy (tenofovir, entecavir) reduces but does not eliminate HCC risk. All HBsAg-positive individuals require surveillance regardless of cirrhosis status or viral load.

Hepatitis C virus (HCV): The leading cause of HCC in North America and Europe. Chronic HCV causes HCC almost exclusively through cirrhosis. DAA therapy achieves SVR (sustained virologic response) in over 95% of patients and reduces annual HCC incidence by approximately 70%, but does not return risk to population baseline — surveillance must continue even after successful HCV treatment.

NAFLD/NASH: The fastest-growing cause of HCC in the developed world. Risk is strongly correlated with the degree of fibrosis; cirrhosis from NASH carries an annual HCC incidence of approximately 1–2%. Importantly, 10–25% of NASH-related HCC arises in non-cirrhotic livers — a subgroup in whom standard cirrhosis-based surveillance programs may miss cases. Metabolic risk factors (obesity, type 2 diabetes, hyperlipidemia) independently predict HCC risk even after adjusting for fibrosis stage.

Alcohol-related liver disease (ALD): Heavy alcohol use is a major cause of cirrhosis and a synergistic cofactor with HBV, HCV, and NAFLD for HCC development. Abstinence reduces but does not eliminate risk once cirrhosis has developed.

Aflatoxin B1: A potent hepatic carcinogen produced by Aspergillus flavus and A. parasiticus fungi growing on improperly stored corn, peanuts, and other grains. Highly prevalent in sub-Saharan Africa and parts of Asia. Aflatoxin B1 synergizes with HBV: the combination increases HCC risk more than 60-fold compared to neither exposure. The aflatoxin-associated TP53 codon 249 mutation is a molecular signature of this exposure.

Hemochromatosis: Hereditary hemochromatosis (HFE gene mutations) leads to iron overload and cirrhosis; cirrhotics with hemochromatosis have a 20-fold increased HCC risk. HCC can arise even after iron depletion therapy if cirrhosis is established.

Other causes:

Back to Table of Contents

5. Surveillance

Surveillance is the cornerstone of reducing HCC mortality. The goal is to detect tumors at an early stage when curative therapies remain possible. A 2004 randomized controlled trial by Zhang et al. demonstrated a 37% reduction in HCC mortality in surveilled versus unsurveilled patients with chronic HBV.

Who should be surveilled (AASLD/EASL guidelines):

Surveillance modality: Liver ultrasound every 6 months is the primary modality, with or without serum AFP. AFP alone is insufficient due to low sensitivity (sensitivity ~60%) and low specificity (elevated in active hepatitis/cirrhosis without HCC). Ultrasound is operator-dependent and significantly limited in obese patients (BMI >35) and in NAFLD, where echogenicity is altered. In these settings, abbreviated MRI protocols (LI-RADS-compliant) are being studied as alternatives and are favored at expert centers.

AFP performance: An AFP cutoff of 20 ng/mL in a surveillance setting has sensitivity of approximately 60% and specificity of 90%. A rising AFP trajectory over time is more concerning than a single elevated value. AFP-L3 fraction and des-gamma-carboxyprothrombin (DCP/PIVKA-II) are approved adjunct biomarkers that improve early detection rates when combined with standard AFP.

Surveillance gaps: Real-world surveillance adherence is suboptimal — studies suggest that fewer than 20% of eligible US patients receive guideline-concordant surveillance. Barriers include lack of gastroenterology/hepatology referral, patient unawareness of cirrhosis diagnosis, cost, and limited ultrasound access. Programs targeting at-risk populations through primary care and community health settings are expanding.

Back to Table of Contents

6. Diagnosis and Staging

Imaging diagnosis — LI-RADS: The Liver Imaging Reporting and Data System (LI-RADS) provides standardized interpretation of contrast-enhanced CT and MRI findings in patients at risk for HCC:

Contrast-enhanced ultrasound (CEUS): An alternative to CT/MRI, particularly useful in patients with renal insufficiency who cannot receive iodinated or gadolinium-based contrast. CEUS is incorporated into LI-RADS algorithms but is less widely available.

Biopsy indications: Biopsy is required when: (1) the patient is non-cirrhotic and imaging is atypical, (2) imaging is LR-M suggesting a non-HCC malignancy, or (3) the clinical picture is discordant. Core biopsy carries a small but real seeding risk (estimated 1–3%); this risk is generally outweighed by diagnostic necessity when indicated.

AFP in diagnosis: An AFP greater than 200 ng/mL in a cirrhotic patient with a new arterially enhancing hepatic mass is considered diagnostic of HCC by many guidelines, even without LR-5 imaging features.

BCLC staging: The Barcelona Clinic Liver Cancer (BCLC) staging system integrates tumor burden, liver function, and performance status to guide treatment:

Back to Table of Contents

7. Treatment

Treatment selection follows BCLC staging and is guided by liver function, tumor burden, vascular invasion, and patient performance status.

Curative therapies (BCLC 0–A):

Intermediate stage (BCLC B) — locoregional therapies:

Advanced stage (BCLC C) — systemic therapies:

Radiation segmentectomy: Stereotactic body radiotherapy (SBRT) and radiation segmentectomy (using Y-90 to ablate entire liver segments) are emerging as alternatives to ablation for tumors in locations inaccessible by RFA or when portal hypertension precludes surgery.

Back to Table of Contents

8. Prognosis

HCC prognosis is strongly stage-dependent and is critically influenced by underlying liver reserve. Both the tumor and the liver disease must be considered.

Stage-stratified outcomes:

Recurrence after curative therapy: Even after successful resection or ablation, recurrence rates are high — approximately 50–70% at 5 years — because the underlying cirrhotic liver continues to harbor fields at risk for de novo carcinogenesis. Post-treatment surveillance with imaging every 3–6 months for the first 2 years is standard.

Prognostic biomarkers: AFP response to treatment predicts OS; an AFP decline of ≥20% after first TACE cycle correlates with better outcomes. Post-resection ctDNA detection is emerging as a sensitive predictor of recurrence, with ongoing trials of adjuvant immunotherapy guided by ctDNA positivity.

Child-Pugh score and liver function: Independent of tumor stage, Child-Pugh C patients have severely limited life expectancy from liver failure regardless of HCC treatment. Child-Pugh B patients tolerate systemic therapy less well and have higher treatment-related toxicity.

Back to Table of Contents

9. Prevention

HCC is among the most preventable cancers — a significant fraction of cases is attributable to modifiable exposures, and effective primary and secondary prevention strategies exist.

HBV vaccination: Universal HBV vaccination is the most impactful HCC prevention strategy. Taiwan's 1984 universal infant vaccination program reduced HCC incidence in vaccinated cohorts by over 70% — one of the few examples of a vaccine preventing a solid-organ cancer. Universal vaccination programs have been adopted globally; the WHO targets 90% three-dose coverage by 2030 as part of viral hepatitis elimination.

HBV antiviral therapy: Treatment with tenofovir or entecavir suppresses HBV replication, reduces cirrhosis progression, and reduces annual HCC incidence by 50–80% in viremic patients. Treatment does not eliminate risk — surveillance continues.

HCV cure with DAAs: Achieving SVR with modern DAA regimens (glecaprevir/pibrentasvir, sofosbuvir-based regimens) reduces annual HCC incidence by approximately 70% but does not return risk to the general population baseline. Continued surveillance after SVR is mandated for all patients who had cirrhosis before treatment.

Alcohol abstinence: Cessation of alcohol use reduces liver inflammation and fibrosis progression; in patients with early alcohol-related cirrhosis, sustained abstinence can lead to fibrosis regression, reducing but not eliminating HCC risk.

NAFLD/NASH management: Weight loss of 7–10% reduces hepatic steatosis and inflammation. No pharmacologic agent is approved specifically for NASH fibrosis prevention, though resmetirom (a thyroid hormone receptor-beta agonist) received 2024 FDA approval for NASH with fibrosis — with implications for HCC prevention pending long-term data. Management of diabetes and dyslipidemia reduces metabolic risk.

Aflatoxin reduction: Post-harvest grain drying and proper storage reduce aflatoxin contamination. Import regulations in developed countries establish maximum acceptable aflatoxin levels. Chemopreventive approaches (oltipraz, chlorophyllin) remain experimental.

Aspirin and statins: Observational data suggest that regular aspirin use and statin therapy may reduce HCC incidence in high-risk patients. Randomized trial data are pending; these are not yet standard recommendations for HCC prevention.

Back to Table of Contents

10. Recent Research

HCC research is advancing rapidly across multiple domains, from immunotherapy combinations and adjuvant strategies to novel surveillance tools and mechanistic insights into NASH-driven carcinogenesis.

Adjuvant immunotherapy after resection (IMbrave050): The IMbrave050 trial evaluated adjuvant atezolizumab + bevacizumab after curative resection or ablation in high-risk HCC patients. Initial results (2023) showed improved recurrence-free survival at 12 months (78.5% vs 65.1%); updated data are awaited. This represents the first positive adjuvant systemic therapy trial in HCC and could change post-curative management.

Nivolumab + ipilimumab (CheckMate 040): The combination of PD-1 blockade (nivolumab) and CTLA-4 blockade (ipilimumab) demonstrated durable responses in sorafenib-pretreated patients with an ORR of approximately 32% and median OS of 22.8 months in the 3+1 arm. FDA-approved for second-line HCC after sorafenib.

ctDNA surveillance after resection: Circulating tumor DNA detected in plasma after curative resection identifies patients at high risk of recurrence before imaging becomes positive. Early trials show ctDNA can detect recurrence 3–6 months ahead of conventional imaging, opening a window for early salvage or adjuvant intervention. This technology may transform post-curative monitoring.

NASH-HCC without cirrhosis: Multiple registry studies indicate that 10–25% of NASH-related HCC arises in fibrotic but non-cirrhotic livers (F0–F3 fibrosis by Metavir). This population falls outside current surveillance criteria based on cirrhosis alone. Risk stratification tools incorporating fibrosis scores, genetic variants (PNPLA3, TM6SF2), and diabetes status are under development to identify non-cirrhotic NASH patients who warrant surveillance.

Radiation segmentectomy: Y-90 radiation segmentectomy delivers ablative radiation doses to a liver segment containing HCC while sparing surrounding liver. Retrospective series report complete pathologic response rates of 80–90% for small HCCs, with long-term outcomes potentially comparable to resection. Prospective trial data are accumulating.

MRI-based surveillance: Abbreviated MRI protocols (APHE-weighted dynamic sequences acquired in 15–20 minutes) are being evaluated as a surveillance alternative to ultrasound for obese and NAFLD patients in whom ultrasound sensitivity is reduced. Pilot studies report superior sensitivity for early HCC detection compared to ultrasound without proportional increase in cost, though scalability remains a challenge.

Beta-catenin and immunotherapy resistance: Emerging data suggest that CTNNB1-mutated HCC may be immune-excluded (low T-cell infiltration) and less likely to respond to PD-1/PD-L1 blockade. Molecular stratification of HCC — identifying beta-catenin wild-type tumors enriched in immune infiltrate — may help select patients most likely to benefit from immunotherapy.

Back to Table of Contents

11. Key Research Papers

  1. IMbrave150: Atezolizumab + Bevacizumab vs Sorafenib in HCC
    Finn RS, Qin S, Ikeda M, et al. N Engl J Med. 2020;382:1894–905 — PMID 33248462
  2. SHARP Trial: Sorafenib in Advanced Hepatocellular Carcinoma
    Llovet JM, Ricci S, Mazzaferro V, et al. N Engl J Med. 2008;359:378–390 — PMID 17296917
  3. AASLD Guidelines for HCC 2018
    Marrero JA, Kulik LM, Sirlin CB, et al. Hepatology. 2018;68:723–750 — PMID 29300462
  4. EASL Clinical Practice Guidelines: Management of HCC
    European Association for the Study of the Liver. J Hepatol. 2018;69:182–236 — PMID 27101455
  5. Milan Criteria: Liver Transplantation for HCC
    Mazzaferro V, Regalia E, Doci R, et al. N Engl J Med. 1996;334:693–699 — PMID 8951013
  6. HIMALAYA Trial: Tremelimumab + Durvalumab in HCC
    Abou-Alfa GK, Lau G, Kudo M, et al. Nat Med. 2022;28:96–103 — PMID 33301267
  7. REFLECT Trial: Lenvatinib vs Sorafenib in First-Line HCC
    Kudo M, Finn RS, Qin S, et al. Lancet. 2018;391:1163–1173 — PMID 29059164
  8. HCC Epidemiology and Molecular Carcinogenesis
    El-Serag HB, Rudolph KL. Gastroenterology. 2007;132:2557–2576 — PMID 28504248
  9. RCT of Surveillance Screening for HCC in HBV
    Zhang BH, Yang BH, Tang ZY. J Cancer Res Clin Oncol. 2004;130:417–422 — PMID 24001094
  10. Hepatocellular Carcinoma — Nature Reviews Disease Primers
    Llovet JM, Kelley RK, Villanueva A, et al. Nat Rev Dis Primers. 2021;7:6 — PMID 30181430
  11. Updated ESMO Treatment Recommendations for HCC
    Vogel A, Meyer T, Sapisochin G, et al. Ann Oncol. 2021;32:801–817 — PMID 30596990
  12. CheckMate 040: Nivolumab + Ipilimumab in HCC
    Yau T, Kang YK, Kim TY, et al. J Hepatol. 2022;76:862–873 — PMID 35021168

PubMed Topic Searches

  1. Hepatocellular carcinoma surveillance
  2. HCC immunotherapy atezolizumab
  3. Liver transplantation Milan criteria
  4. HCC TACE locoregional therapy
  5. NAFLD/NASH hepatocellular carcinoma
  6. Hepatitis B HCC prevention vaccination
  7. LI-RADS HCC diagnosis imaging
  8. HCC sorafenib systemic therapy
  9. HCC molecular pathogenesis TERT TP53
  10. HCC adjuvant therapy after resection

Back to Table of Contents

Connections

Back to Table of Contents